WO2007139176A1 - ホスフィン遷移金属錯体、その製造方法及び抗癌剤 - Google Patents
ホスフィン遷移金属錯体、その製造方法及び抗癌剤 Download PDFInfo
- Publication number
- WO2007139176A1 WO2007139176A1 PCT/JP2007/061046 JP2007061046W WO2007139176A1 WO 2007139176 A1 WO2007139176 A1 WO 2007139176A1 JP 2007061046 W JP2007061046 W JP 2007061046W WO 2007139176 A1 WO2007139176 A1 WO 2007139176A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- transition metal
- substituent
- metal complex
- phosphine
- Prior art date
Links
- -1 Phosphine transition metal Chemical class 0.000 title claims abstract description 93
- 229910052723 transition metal Inorganic materials 0.000 title claims abstract description 74
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 229910000073 phosphorus hydride Inorganic materials 0.000 title claims abstract description 64
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 33
- 238000004519 manufacturing process Methods 0.000 title description 9
- 125000001424 substituent group Chemical group 0.000 claims abstract description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 28
- 229910052737 gold Inorganic materials 0.000 claims abstract description 24
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 23
- 239000010931 gold Substances 0.000 claims abstract description 23
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 22
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000000126 substance Substances 0.000 claims abstract description 21
- 229910052802 copper Inorganic materials 0.000 claims abstract description 20
- 239000010949 copper Substances 0.000 claims abstract description 20
- 229910052709 silver Inorganic materials 0.000 claims abstract description 20
- 239000004332 silver Substances 0.000 claims abstract description 20
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 18
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 17
- 150000001450 anions Chemical class 0.000 claims abstract description 15
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims abstract description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 12
- 150000003624 transition metals Chemical group 0.000 claims abstract description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 8
- 150000003003 phosphines Chemical class 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 22
- MAWPZHTVBDJQKE-UHFFFAOYSA-M tert-butyl-[3-[tert-butyl(methyl)phosphanyl]quinoxalin-2-yl]-methylphosphane;chlorogold Chemical compound [Au]Cl.C1=CC=C2N=C(P(C)C(C)(C)C)C(P(C)C(C)(C)C)=NC2=C1.C1=CC=C2N=C(P(C)C(C)(C)C)C(P(C)C(C)(C)C)=NC2=C1 MAWPZHTVBDJQKE-UHFFFAOYSA-M 0.000 description 19
- 230000001093 anti-cancer Effects 0.000 description 16
- DRZBLHZZDMCPGX-UHFFFAOYSA-N tert-butyl-[3-[tert-butyl(methyl)phosphanyl]quinoxalin-2-yl]-methylphosphane Chemical compound C1=CC=C2N=C(P(C)C(C)(C)C)C(P(C)C(C)(C)C)=NC2=C1 DRZBLHZZDMCPGX-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 12
- BWJRMVLPCQPWGR-UHFFFAOYSA-N boron;phosphane Chemical compound [B].P BWJRMVLPCQPWGR-UHFFFAOYSA-N 0.000 description 12
- 201000011510 cancer Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- SPSSDDOTEZKOOV-UHFFFAOYSA-N 2,3-dichloroquinoxaline Chemical compound C1=CC=C2N=C(Cl)C(Cl)=NC2=C1 SPSSDDOTEZKOOV-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 229910003771 Gold(I) chloride Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000004437 phosphorous atom Chemical group 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- LJPFWCBUSPMLGW-UHFFFAOYSA-N B.CPC(C)(C)C Chemical compound B.CPC(C)(C)C LJPFWCBUSPMLGW-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical compound [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N isopropyl alcohol Natural products CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- ZDQSBZHWCMBILH-UHFFFAOYSA-N tert-butyl(methyl)phosphane Chemical compound CPC(C)(C)C ZDQSBZHWCMBILH-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- WHXSMMKQMYFTQS-BJUDXGSMSA-N (6Li)Lithium Chemical compound [6Li] WHXSMMKQMYFTQS-BJUDXGSMSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- ZCWPHDXKEDBCER-UHFFFAOYSA-N 2,5-diphenyl-2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=CC=CC=C1C1=[NH+]N(C=2C=CC=CC=2)N=N1 ZCWPHDXKEDBCER-UHFFFAOYSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 206010062038 Lip neoplasm Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 229910021612 Silver iodide Inorganic materials 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- NEIHULKJZQTQKJ-UHFFFAOYSA-N [Cu].[Ag] Chemical compound [Cu].[Ag] NEIHULKJZQTQKJ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 210000002858 crystal cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical compound [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 238000009775 high-speed stirring Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000009023 maxillary cancer Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000017708 myomatous neoplasm Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000026517 ureter neoplasm Diseases 0.000 description 1
- 201000011476 ureteral benign neoplasm Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
- C07F9/650994—Six-membered rings having the nitrogen atoms in the positions 1 and 4 condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/12—Gold compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
Definitions
- Phosphine transition metal complex its production method and anticancer agent
- the present invention relates to a novel phosphine transition metal complex, a method for producing the same, and an anticancer agent containing the phosphine transition metal complex.
- Cisbratin has been well known as a substance having high anticancer activity against cancer cells.
- phosphine transition metal complexes having a specific structure such as 1,2-bis (diphenylphosphino) ethane are known to be compounds having anticancer activity comparable to cisplatin.
- Patent Literature:! ⁇ 2 1,2-bis (diphenylphosphino)
- Patent Document 1 or Patent Document 2 proposes a phosphine transition metal complex represented by the following general formula (4).
- Phosphine transition metal complexes that are halogen atoms such as
- R 6 to: R 9 is a phenyl group, an ethyl group or a mono-substituted phenyl group of the same group,
- A is (CH 2) n— or cis_CH ⁇ CH—,
- M ′ is gold, silver Copper,
- B is halogen
- Patent Document 1 Japanese Patent Publication No. 10-509957
- Patent Document 2 Japanese Patent Application Laid-Open No. 61-10594 Disclosure of the invention
- an object of the present invention is to provide an anticancer agent having a novel chemical structure and high anticancer activity.
- the present inventors have conducted extensive research on a novel phosphine transition metal complex having an anticancer effect in such a situation, and as a result, the phosphine transition metal complex having a specific structure is superior in anti-cancer activity. It has been found that it has cancer activity, and the present invention has been completed.
- the present invention (1) includes the following general formula (1):
- R 1 and R 2 are a linear or branched alkyl group, a cycloalkyl group, a cycloalkyl group having a substituent, an adamantyl group, a phenyl group, or a phenyl group having a substituent.
- R 3 and R 4 may be a hydrogen atom or a linear or branched chain, and may be the same group or different groups. Represents an alkyl group, and has carbon atoms:!
- R 3 and R 4 may be bonded to each other to form a saturated or unsaturated ring;
- the saturated or unsaturated ring which may be formed may have a substituent, and M represents a transition metal atom selected from the group consisting of gold, copper and silver.
- the x_ represents an anion.
- the present invention (2) includes the following general formula (2):
- R 1 and R 2 are a linear or branched alkyl group, a cycloalkyl group, a cycloalkyl group having a substituent, an adamantyl group, a phenyl group, or a phenyl group having a substituent.
- R 5 represents a monovalent substituent
- n represents 0 to Represents an integer of 4.
- M represents a transition metal atom selected from the group consisting of gold, copper, and silver
- X— represents an anion.
- the phosphine transition metal complex of the present invention (1) is characterized by being represented by the following:
- the present invention (3) is characterized in that either R 1 is a t_butyl group or an adamantyl group, and R 2 is a methyl group.
- a phosphine transition metal complex is provided.
- the present invention includes the following general formula (3):
- R 1 and R 2 are a linear or branched alkyl group, a cycloalkyl group, a cycloalkyl group having a substituent, an adamantyl group, a phenyl group, or a phenyl group having a substituent.
- R 3 and R 4 may be a hydrogen atom or a linear or branched chain, and may be the same group or different groups. Indicates an alkyl group, carbon The number is:! ⁇ 6.
- R 3 and R 4 may be bonded together to form a saturated or unsaturated ring, and the saturated or unsaturated ring may have a substituent.
- R 1 and R 2 are a linear or branched alkyl group, a cycloalkyl group, a cycloalkyl group having a substituent, an adamantyl group, a phenyl group, or a phenyl group having a substituent.
- R 3 and R 4 may be a hydrogen atom or a linear or branched chain, and may be the same group or different groups.
- R 3 and R 4 may be bonded to each other to form a saturated or unsaturated ring;
- the saturated or unsaturated ring which may form may have a substituent, and M represents a transition metal atom selected from the group consisting of gold, copper and silver. Indicates an anion.
- a phosphine transition metal complex represented by the formula (1) is obtained.
- the present invention (5) provides an anticancer agent comprising the phosphine transition metal complex according to any one of the present inventions (1) to (3).
- the phosphine transition metal complex of the present invention is a phosphine transition metal complex represented by the general formula (1).
- R 1 and R 2 are a linear or branched alkyl group, a cycloalkyl group, a cycloalkyl group having a substituent, an adamantyl group, a phenyl group, or a substituted group.
- a phenyl group having a group is shown.
- R 1 and R 2 have carbon numbers:! -10.
- R 1 and R 2 may be the same group or different groups.
- Examples of the alkyl group related to R 1 and R 2 include, for example, a methyl group, an ethyl group, an isopropyl group, an n_propyl group, an isobutyl group, an n_butyl group, a sec_butyl group, a tert_butyl group, and an isohexyl group. Examples thereof include a butyl group, an n_heptyl group, an isohexyl group, and an n_hexyl group.
- examples of the cycloalkyl group related to R 1 and R 2 include a cyclopentyl group and a cyclohexyl group.
- R 1 and R 2 are a cycloalkyl group having a substituent or a phenyl group having a substituent
- the substituent for the cycloalkyl group having a substituent or the phenyl group having a substituent may be an alkyl group Nitro group, amino group, hydroxyl group, fluorine group, black group, bromo group, and iodine group.
- R 1 is a t_butyl group or an adamantyl group and R 2 is a methyl group from the viewpoint of high anticancer activity.
- R 3 and R 4 represent a hydrogen atom or a linear or branched alkyl group.
- R 3 and R 4 have carbon numbers:! -6.
- R 3 and R 4 may be the same group or different groups.
- R 3 and R 4 may be bonded to each other to form a saturated or unsaturated ring. When R 3 and R 4 are bonded to each other to form a saturated or unsaturated ring, they are saturated. Alternatively, the unsaturated ring may have a substituent.
- Examples of the alkyl group related to R 3 and R 4 include ethyl group, isopropyl group, n-propinole group, isobutyl group, n-butyl group, sec-butyl group, tert-butyl group, isoheptyl group. Nore group, n butyl group, isohexyl group, n xyl group, cyclopentyl group, cyclohexyl group and the like can be mentioned.
- R 3 and R 4 are bonded to each other to form a saturated or unsaturated ring
- the ring formed by bonding R 3 and R 4 to each other is saturated or unsaturated.
- a 5-membered ring or a 6-membered ring examples thereof include a phenyl group, a cyclohexenole group, and a cyclopentyl group.
- the ring R 3 and R 4 are bonded is formed to each other, substituted monovalent with the rings have a substituent good instrument R 3 and R 4 also have been bonded to each other to form monovalent Examples of the group include a linear or branched chain alkyl group having a carbon number of 15, a nitro group, an amino group, a hydroxyl group, a fluoro group, a black mouth group, a bromo group, and a odo group. .
- M represents a transition metal atom selected from the group consisting of gold, copper and silver. And it is preferable that M is a gold atom in terms of increasing anticancer activity.
- X- represents an anion, for example, chlorine ion, bromine ion, iodine ion, boron tetrafluoride ion, hexafluorophosphate ion, perchlorate ion, or the like.
- X is preferably a chlorine ion, bromine ion, or iodine ion, because it has a high anticancer activity.
- R 3 and R 4 are bonded to each other to form a benzene ring, which is preferable in that the anticancer activity is enhanced. Les.
- the phosphine transition metal complex in which R 3 and R 4 are bonded to each other to form a benzene ring is a phosphine transition metal complex represented by the general formula (2).
- R 1 R 2 , M and X— have the same meanings as R 1 R 2 , M and X_ in the general formula (1).
- R 5 represents a monovalent substituent.
- substituent according to R 5 include a linear or branched chain alkyl group having 1 to 5 carbon atoms, a nitro group, an amino group, a hydroxyl group, a fluoro group, a black mouth group, a bromo group, The odo group is mentioned.
- N represents an integer of 0 to 4.
- the phosphine transition metal complex represented by the general formula (1) is R in the formula
- a phosphine transition metal complex having an asymmetric center on a phosphorus atom represented by
- R 2 , R 3 , R 4 , M and X_ are the same as R 2 , R 3 in the general formula (1).
- the phosphine transition metal complex represented by the general formula (5) has four asymmetric phosphorus atoms, there are many isomers. In the present invention, these isomers are present. There are no particular restrictions on the type of the. Specifically, these isomers are phosphorus sources.
- the solid on the child may be composed of a single enantiomer force, such as (R, R) (R, or (S, S) (S, S), and (R, R) ( (S, S) may be composed of a racemate of the ligand, and may be composed of meso strengths of each other, such as (R, S) (S, R). In addition, it may be composed of one enantiomer and its meso form (R, R) (S, R).
- the phosphine transition metal complex represented by the general formula (1) includes a phosphine derivative represented by the general formula (3),
- the method for producing a phosphine transition metal complex of the present invention comprises a phosphine derivative represented by the general formula (3),
- R 2 , R 3 and R 4 have the same meanings as the general formula (1) R 3 and R 4 . That, R 1 R 2, R 3 and R 4 in the general formula (3) correspond respectively to R 1 R 2, R 3 and R 4 in the general formula (1).
- the phosphine derivative represented by the general formula (3) for example, as shown in the following reaction formula (9), reacts 2, 3 dichloroquinoxaline (6) and phosphine borane (7), Bis (phosphine borane) quinoxaline (8) is obtained, and then the resulting bis (phosphine borane) quinoxaline (8) is subjected to a deboration reaction.
- reaction formula (9) the reaction between 2,3-dichloroquinoxaline (6) and phosphine monoborane (7) is, for example, in the presence of a base such as n_butyllithium in the presence of tetrahydrofuran or the like.
- the reaction is carried out in an inert solvent at 78 to 30 ° C for 1 to 24 hours.
- 2,3-Dichloromouth quinoxaline (6) and phosphine monoborane (7) are produced by known methods.
- 2,3-dichroic quinoxaline (6) is commercially available
- phosphine-borane (7) is disclosed in, for example, JP-A 2003-300988, JP-A 2001-253889, J. Org.Chem, 2000, vol.65, P4185-4188, etc.
- the deboraneation reaction of bis (phosphine monoborane) quinoxaline (8) is carried out in a reaction system containing bis (phosphine monoborane) quinoxaline (8) by adding N, N, ⁇ ', ⁇ ', —Deboranating agent such as tetramethylethylenediamine (TMEDA) is added and reacted at 0 to 100 ° C. for 10 minutes to 3 hours.
- TEDA tetramethylethylenediamine
- the transition metal salt according to the method for producing a phosphine transition metal complex of the present invention is a salt of gold ion, copper ion or silver ion and anion, gold, copper or silver halide, nitrate, excess Examples thereof include chlorate, tetrafluoroborate, hexafluorophosphate, and the like.
- the valence of the transition metal ion in the gold, copper or silver transition metal salt is monovalent.
- the transition metal salt of gold, copper or silver may be a transition metal salt or anion, or two or more transition metal salts in which one or both of them are different.
- Preferred gold transition metal salts include, for example, gold chloride (I) acid, gold chloride (1), Rabutylammonium chloride 'salt gold (I), etc. ("Fifth edition experimental chemistry course 21", editor Japan Chemical Society, publisher Maruzen, publication date March 30, 2004, p366-380 Aust. J. Chemm., 1997, 50, pages 775-778).
- Preferred copper transition metal salts include, for example, copper chloride (I), copper bromide (I), copper iodide (I), etc. (“5th edition Experimental Chemistry Course 21", editor Nihon Kagaku). Society, issue place Maruzen, issue date March 30, 2004, P 34 9-361).
- Preferred silver transition metal salts include, for example, silver chloride (I), silver bromide (1), silver iodide (I) and the like (“5th edition Experimental Chemistry Lecture 21”, edited by the Japan Chemical Society). Issue place Maruzen, issue date March 30, 2004, p36:! -366).
- the transition metal salt according to the method for producing a phosphine transition metal complex of the present invention may be an anhydride or a hydrate.
- the molar specific force S of the phosphine derivative represented by the general formula (3) with respect to the transition metal salt of gold, copper or silver is 1 to 5 times mol, preferably 1.8 to 2.2 times mol.
- the phosphine transition metal complex represented by the general formula (1) can be obtained by reacting at 0 to 25 ° C, preferably 0.5 to 48 hours, preferably 1 to 3 hours. And after completion
- the anion of the phosphine transition metal complex represented by the general formula (1) obtained by the method for producing a phosphine transition metal complex of the present invention is converted into another anion to have a desired anion.
- a phosphine transition metal complex represented by the general formula (1) can be produced.
- a phosphine transition metal complex in which X- in the general formula (1) is a halogen ion is synthesized by the method for producing a phosphine transition metal complex of the present invention, and then the general formula (1
- the phosphine transition metal complex in which X- is a halogen ion and an inorganic acid, an organic acid or an alkali metal salt thereof having a desired anion in a suitable solvent are reacted with each other.
- a phosphine transition metal complex in which X in the general formula (1) is a desired anion can be obtained (Japanese Patent Laid-Open Nos. 10-147590, 10-114782, and 61-10594). reference).
- the optically active phosphine transition metal complex is obtained by using optically active phosphine borane (7) as a starting material in the reaction formula (9). ), And then reacting the obtained optically active phosphine derivative represented by the general formula (3) with a transition metal salt of gold, copper or silver. .
- the optically active phosphine-borane (7) can be obtained by using, for example, methods such as JP 2001-253889, JP 2003-300988, J. Org. Chem, 2000, vol. 65, P4185-4188. Manufactured. Further, by using phosphine monoborane (7) in which R 1 and R 2 are different from each other as a starting material, the phosphine transition metal complex represented by the general formula (5) is produced.
- the phosphine transition metal complex of the present invention has high anticancer activity as described later, it can be used as an anticancer agent.
- the anticancer agent of the present invention contains one or more of the phosphine transition metal complexes represented by the general formula (1).
- phosphine transition metal complexes represented by the general formula (1) a phosphine transition metal complex having an asymmetric center on a phosphorus atom, that is, a phosphine represented by the general formula (5)
- a transition metal complex as described above, there are many isomers, but the anticancer agent of the present invention may be one or more of these isomers.
- the type of cancer to which the anticancer agent of the present invention is applied is not particularly limited.
- the anticancer agent of the present invention can be administered to humans or animals in various forms, and the administration form of the anticancer agent of the present invention may be orally administered.
- parenteral administration such as intravenous, intramuscular, subcutaneous or intradermal injection, rectal administration or transmucosal administration may be used.
- dosage form suitable for oral administration include tablets, pills, granules, powders, capsules, solutions, suspensions, emulsions, syrups, etc.
- compositions suitable for parenteral administration examples include injections, drops, nasal drops, sprays, inhalants, suppositories, or transdermal absorbents such as ointments, creams, powdered coatings, liquid coatings, patches, and the like.
- examples of the dosage form of the anticancer agent of the present invention include embedding pellets and sustained-release preparations by known techniques.
- preferable administration forms, preparation forms, and the like are appropriately selected by a doctor depending on the age, sex, constitution, symptoms, treatment timing, etc. of the patient.
- the anticancer agent of the present invention is a solid preparation such as a tablet, pill, powder, powder, granule or the like
- the solid preparation usually contains a phosphine transition metal complex represented by the general formula (1).
- phosphine transition metal complex represented by the general formula (1).
- Appropriate additives according to the law such as lactose, sucrose, D-mannitol, corn starch, synthetic or natural gums, excipients such as crystalline cellulose, starch, hydroxypropinocellulose, hydroxypropylmethylcellulose, Disintegrants such as gum arabic, gelatin, polyvinylpyrrolidone, etc.
- Disintegrants such as sodium carbonate, starch, corn starch, sodium alginate, tarc, magnesium stearate, sodium stearate Lubricants such as calcium carbonate, sodium carbonate, calcium phosphate
- Lubricants such as calcium carbonate, sodium carbonate, calcium phosphate
- Tablets and the like may be subjected to sugar coating, gelatin, enteric coating, film coating, etc., if necessary using a coating agent such as hydroxypropylmethylcellulose, sucrose, polyethylene glycol, titanium oxide or the like.
- the anticancer agent of the present invention is a liquid preparation such as injections, eye drops, nasal drops, inhalants, sprays, lotions, syrups, solutions, suspensions, emulsions, etc.
- the preparation comprises a phosphine transition metal complex represented by the general formula (1), an appropriate buffer solution such as purified water, phosphate buffer solution, physiological saline solution such as physiological saline, Ringer's solution, lock solution, Cocoa butter, dissolved in vegetable oils such as sesame oil and olive oil, mineral oils, higher alcohols, higher fatty acids, ethanol and other organic solvents, etc.
- infiltrant polyoxyethylene hydrogenated castor oil, polyethylene Surfactants such as glycols, solubilizers such as sodium phosphate, stabilizers such as sugars, sugar alcohols and albumins, preservatives such as parabens, isotonic agents such as sodium chloride sodium salt, glucose and glycerin,
- buffer, soothing agent, anti-adsorption agent, moisturizer, antioxidant, colorant, sweetener, flavor, fragrance, etc. as appropriate, sterilized aqueous solution, non-aqueous solution, suspension, It is adjusted as ribosome or emulsion.
- the injection preferably has a physiological pH. It is particularly preferable that the injection has a pH in the range of 6-8.
- the anticancer agent of the present invention is a semi-solid preparation such as a lotion, cream or ointment
- these semi-solid preparations contain a phosphine transition metal complex represented by the above general formula (1) as a fat or oil.
- a phosphine transition metal complex represented by the above general formula (1) as a fat or oil.
- the content of the phosphine transition metal complex represented by the general formula (1) in the anticancer agent of the present invention varies depending on the dosage form, the severity, the intended dosage, etc. Is from 0.001 to 80% by mass, preferably from 0.:! To 50% by mass, based on the total mass of the anticancer agent of the present invention.
- the dose of the anticancer agent of the present invention is determined by a doctor as appropriate according to conditions such as the age, sex, weight, symptoms, and administration route of the patient.
- the amount of the active ingredient per unit is in the range of about 1 ag / kg to 1,000 mg / kg, preferably in the range of about 10 ⁇ g / kg to 10 mg / kg.
- the above-mentioned dose of anticancer agent may be administered once a day, or may be administered in several divided portions (for example, about 2 to 4 times).
- the anticancer agent of the present invention can be used in combination with known chemotherapy, surgical treatment, radiotherapy, hyperthermia, immunotherapy and the like.
- the phosphine transition metal complex represented by the general formula (1) is higher in water solubility than the phosphine transition metal complex proposed in Patent Document 1 or Patent Document 2, so that it is administered when an anticancer agent is used. A small amount without selecting the form or formulation, because it works effectively on the affected area Therefore, it has the advantage that the dose can be reduced.
- the organic phase was washed with saturated brine and dried over sodium sulfate.
- the yield was 2.27 g, and the yield was 80%.
- 2,3_bis (te rt-butylmethylphosphino) quinoxaline (3a) prepared in Synthesis Example 1 1.33 g (3.98 mmol) and degassed THF were calorieated. . To this was added 1.02 mg (l.99 mmol) of tetraptyl ammonium gold (I) dichloride, and the mixture was stirred at room temperature for 20 hours. The precipitate was filtered off and the filtrate was dried.
- HL-60 human acute myeloid leukemia cells
- RP MI1640 Rosewell Park Memorial Institute medium
- the cells were washed with PBS, and after counting the number of cells, a 1 X 10 6 cell Zml suspension was prepared using the same medium. The suspension was added to a sterile 96-well microplate to a density of 50000 cell Z-wells.
- the absorbance at 630 nm was measured and subtracted from the actual measurement. This was evaluated as the number of viable cells, and the 50% cell growth inhibitory concentration (I C) was calculated. The IC value was calculated at least three times in the same way.
- Example 2 Bis (2,3-bis (tert-butylmethylphosphino) quinoxaline) gold (I) Chloride (la) 50 g, lactose 400 g and corn starch 50 g obtained in the same manner as in Example 1 were mixed in a blender. To obtain a powder.
- Example 8 Bis (2,3-bis (tert-butylmethylphosphino) quinoxaline) gold (I) chloride (la) 2 g, liquid paraffin 6 g, beeswax 2 g, self-emulsifying monostearin obtained in the same manner as in Example 1 3 g of acid glyceride and 5 g of white petrolatum were heated and dissolved and dispersed to obtain an ointment.
- an anticancer agent having a novel chemical structure and high anticancer activity.
- an industrially advantageous method for producing a phosphine transition metal complex represented by the general formula (1) can be provided.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07744457A EP2030978B1 (en) | 2006-06-01 | 2007-05-31 | Phosphine transition metal complex, method for producing the same and antitumor agent |
CA2653664A CA2653664C (en) | 2006-06-01 | 2007-05-31 | Phosphine transition metal complex, process for producing same, and anticancer agent |
US12/302,517 US8278303B2 (en) | 2006-06-01 | 2007-05-31 | Phosphine transition metal complex, process for producing same, and anticancer agent |
CN2007800200839A CN101460512B (zh) | 2006-06-01 | 2007-05-31 | 膦过渡金属配位化合物、其制造方法和抗癌剂 |
KR1020087031933A KR101372659B1 (ko) | 2006-06-01 | 2007-05-31 | 포스핀 전이 금속 착체, 그의 제조 방법 및 항암제 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-153422 | 2006-06-01 | ||
JP2006153422A JP4476244B2 (ja) | 2006-06-01 | 2006-06-01 | ホスフィン遷移金属錯体、その製造方法及び抗癌剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007139176A1 true WO2007139176A1 (ja) | 2007-12-06 |
Family
ID=38778694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/061046 WO2007139176A1 (ja) | 2006-06-01 | 2007-05-31 | ホスフィン遷移金属錯体、その製造方法及び抗癌剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US8278303B2 (ja) |
EP (1) | EP2030978B1 (ja) |
JP (1) | JP4476244B2 (ja) |
KR (1) | KR101372659B1 (ja) |
CN (1) | CN101460512B (ja) |
CA (1) | CA2653664C (ja) |
WO (1) | WO2007139176A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010208993A (ja) * | 2009-03-10 | 2010-09-24 | Nippon Chem Ind Co Ltd | 2,2’−ビス(ジアルキルホスフィノ)ビフェニル化合物及びその製造方法並びに該化合物を配位子とする金属錯体 |
WO2011078122A1 (ja) * | 2009-12-21 | 2011-06-30 | 日本化学工業株式会社 | 抗がん剤 |
WO2011078121A1 (ja) * | 2009-12-21 | 2011-06-30 | 日本化学工業株式会社 | 抗がん剤 |
CN102464675A (zh) * | 2010-11-12 | 2012-05-23 | 上海医药工业研究院 | 具有抗肿瘤活性的金络合物及其可药用衍生物 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011129365A1 (ja) * | 2010-04-14 | 2011-10-20 | 日本化学工業株式会社 | 抗がん剤 |
JP5889550B2 (ja) * | 2011-06-20 | 2016-03-22 | 日本化学工業株式会社 | 抗がん剤組成物 |
CN103385851B (zh) * | 2012-05-08 | 2015-09-09 | 上海医药工业研究院 | 用于抗癌的可注射用药物组合物 |
JP6682703B2 (ja) * | 2017-07-11 | 2020-04-15 | 日本化学工業株式会社 | 光学活性な2,3−ビスホスフィノピラジン誘導体の製造方法及び光学活性なホスフィン遷移金属錯体の製造方法 |
JP6641328B2 (ja) | 2017-08-08 | 2020-02-05 | 日本化学工業株式会社 | 2,3−ビスホスフィノピラジン誘導体の製造方法及びホスフィン遷移金属錯体の製造方法 |
JP6802232B2 (ja) | 2018-10-03 | 2020-12-16 | 日本化学工業株式会社 | ホスフィン遷移金属錯体、その製造方法及び抗がん剤 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6110594A (ja) | 1984-06-04 | 1986-01-18 | スミスクライン・ベツクマン・コーポレイシヨン | ホスフイノ‐炭化水素‐金、銀または銅錯体含有腫瘍細胞成長抑制医薬組成物 |
JPH10114782A (ja) | 1996-10-08 | 1998-05-06 | Nippon Chem Ind Co Ltd | 第四級ホスホニウム有機酸塩及びその製造方法 |
JPH10147590A (ja) | 1996-11-19 | 1998-06-02 | Nippon Chem Ind Co Ltd | 第四級ホスホニウム無機酸塩及びその製造方法 |
JPH10509957A (ja) | 1994-12-09 | 1998-09-29 | グリフィス ユニヴァーシティ | 抗癌剤 |
US5843993A (en) * | 1997-03-14 | 1998-12-01 | The Curators Of The University Of Missouri | Hydroxyalkyl phosphine gold complexes for use as diagnostic and therapeutic pharmaceuticals and method of making same |
JP2001253889A (ja) | 2000-03-14 | 2001-09-18 | Nippon Chem Ind Co Ltd | ホスフィン・ボラン誘導体の製造方法 |
JP2003300988A (ja) | 2002-04-08 | 2003-10-21 | Nippon Chem Ind Co Ltd | 光学活性第2級ホスフィンボラン誘導体及びその中間体の製造方法 |
JP2007056007A (ja) * | 2005-07-25 | 2007-03-08 | Chiba Univ | 2,3−ビス(ジアルキルホスフィノ)ピラジン誘導体及びその製造方法、並びに該誘導体を配位子とする金属錯体 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4234729A (en) * | 1979-06-18 | 1980-11-18 | E. I. Du Pont De Nemours And Company | Phosphine oxide-substituted pyrimidines |
-
2006
- 2006-06-01 JP JP2006153422A patent/JP4476244B2/ja not_active Expired - Fee Related
-
2007
- 2007-05-31 WO PCT/JP2007/061046 patent/WO2007139176A1/ja active Application Filing
- 2007-05-31 CA CA2653664A patent/CA2653664C/en not_active Expired - Fee Related
- 2007-05-31 KR KR1020087031933A patent/KR101372659B1/ko active IP Right Grant
- 2007-05-31 CN CN2007800200839A patent/CN101460512B/zh not_active Expired - Fee Related
- 2007-05-31 US US12/302,517 patent/US8278303B2/en active Active
- 2007-05-31 EP EP07744457A patent/EP2030978B1/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6110594A (ja) | 1984-06-04 | 1986-01-18 | スミスクライン・ベツクマン・コーポレイシヨン | ホスフイノ‐炭化水素‐金、銀または銅錯体含有腫瘍細胞成長抑制医薬組成物 |
JPH10509957A (ja) | 1994-12-09 | 1998-09-29 | グリフィス ユニヴァーシティ | 抗癌剤 |
JPH10114782A (ja) | 1996-10-08 | 1998-05-06 | Nippon Chem Ind Co Ltd | 第四級ホスホニウム有機酸塩及びその製造方法 |
JPH10147590A (ja) | 1996-11-19 | 1998-06-02 | Nippon Chem Ind Co Ltd | 第四級ホスホニウム無機酸塩及びその製造方法 |
US5843993A (en) * | 1997-03-14 | 1998-12-01 | The Curators Of The University Of Missouri | Hydroxyalkyl phosphine gold complexes for use as diagnostic and therapeutic pharmaceuticals and method of making same |
JP2001253889A (ja) | 2000-03-14 | 2001-09-18 | Nippon Chem Ind Co Ltd | ホスフィン・ボラン誘導体の製造方法 |
JP2003300988A (ja) | 2002-04-08 | 2003-10-21 | Nippon Chem Ind Co Ltd | 光学活性第2級ホスフィンボラン誘導体及びその中間体の製造方法 |
JP2007056007A (ja) * | 2005-07-25 | 2007-03-08 | Chiba Univ | 2,3−ビス(ジアルキルホスフィノ)ピラジン誘導体及びその製造方法、並びに該誘導体を配位子とする金属錯体 |
Non-Patent Citations (9)
Title |
---|
"Jikken Kagaku Koza", vol. 21, 30 March 2004, MARUZEN, pages: 349 - 361 |
"Jikken Kagaku Koza", vol. 21, 30 March 2004, MARUZEN, pages: 361 - 366 |
"Jikken Kagaku Koza", vol. 21, 30 March 2004, MARUZEN, pages: 366 - 380 |
AUST. J. CHEMM., 1997, pages 775 - 778 |
IMAMOTO T. ET AL.: "An Air-Stable P-Chiral Phosphine Ligand for Highly Enantioselective Transition-Metal-Catalyzed Reactions", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 127, no. 34, 2005, pages 11934 - 11935, XP003019747 * |
J. ORG. CHEM., vol. 65, 2000, pages 4185 - 4188 |
MCKEAGE M.J. ET AL.: "Antitumor activity of gold(I), silver(I) and copper(I) complexes containing chiral tertiary phosphines", METAL-BASED DRUGS, vol. 5, no. 4, 1998, pages 217 - 223, XP009066374 * |
See also references of EP2030978A4 * |
T. MOSMANN, J. LMMUNNOL. METHOD, vol. 65, 1983, pages 55 - 63 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010208993A (ja) * | 2009-03-10 | 2010-09-24 | Nippon Chem Ind Co Ltd | 2,2’−ビス(ジアルキルホスフィノ)ビフェニル化合物及びその製造方法並びに該化合物を配位子とする金属錯体 |
US8198471B2 (en) | 2009-03-10 | 2012-06-12 | Nippon Chemical Industrial Co., Ltd. | 2, 2′-bis (dialkylphosphino) biphenyl compound, production method thereof, and metal complex comprising the compound as ligand |
WO2011078122A1 (ja) * | 2009-12-21 | 2011-06-30 | 日本化学工業株式会社 | 抗がん剤 |
WO2011078121A1 (ja) * | 2009-12-21 | 2011-06-30 | 日本化学工業株式会社 | 抗がん剤 |
US10111892B2 (en) | 2009-12-21 | 2018-10-30 | Nippon Chemical Industrial Co., Ltd. | Anti-cancer agent |
CN102464675A (zh) * | 2010-11-12 | 2012-05-23 | 上海医药工业研究院 | 具有抗肿瘤活性的金络合物及其可药用衍生物 |
Also Published As
Publication number | Publication date |
---|---|
EP2030978B1 (en) | 2011-06-29 |
CN101460512A (zh) | 2009-06-17 |
CA2653664A1 (en) | 2007-12-06 |
EP2030978A1 (en) | 2009-03-04 |
CA2653664C (en) | 2012-11-27 |
US8278303B2 (en) | 2012-10-02 |
EP2030978A4 (en) | 2010-02-10 |
CN101460512B (zh) | 2011-11-23 |
JP2007320909A (ja) | 2007-12-13 |
US20100048894A1 (en) | 2010-02-25 |
JP4476244B2 (ja) | 2010-06-09 |
KR20090024212A (ko) | 2009-03-06 |
KR101372659B1 (ko) | 2014-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007139176A1 (ja) | ホスフィン遷移金属錯体、その製造方法及び抗癌剤 | |
JP5015451B2 (ja) | ホスフィン遷移金属錯体、その製造方法およびそれを含有する抗癌剤 | |
JP5090180B2 (ja) | ホスフィン遷移金属錯体、その製造方法およびそれを含有する抗癌剤 | |
JP5722234B2 (ja) | 抗がん剤の製造方法 | |
JP5722233B2 (ja) | 抗がん剤の製造方法 | |
JP5889550B2 (ja) | 抗がん剤組成物 | |
JP5646606B2 (ja) | 抗がん剤の製造方法 | |
JP6802232B2 (ja) | ホスフィン遷移金属錯体、その製造方法及び抗がん剤 | |
JP5161434B2 (ja) | 抗癌剤 | |
US7390915B1 (en) | Phosphine transition metal complex having ferrocene skeleton, process for making the same, and anti-cancer agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780020083.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07744457 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2653664 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6772/CHENP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007744457 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087031933 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12302517 Country of ref document: US |